AI may predict heart risk in cancer patients
NCT ID NCT07191730
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
This study aims to develop a machine learning tool to predict heart damage in 600 cancer patients receiving certain chemotherapy drugs (anthracyclines or HER2-targeted therapies). Researchers will collect data over one year to see who develops heart problems. The goal is to create a more accurate risk score than current methods, helping doctors identify high-risk patients early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Caen
RECRUITINGCaen, France
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a better way to identify which cancer patients are at high risk of heart problems from their treatment, allowing for closer monitoring or preventive measures.
What could go wrong
This is an observational study, not a treatment trial. The machine learning model may not prove accurate enough for widespread use, and results may not apply to all patient groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.